SIMCERE PHARMA (02096) spent 10.1667 million Hong Kong dollars to repurchase 1.49 million shares on November 18th.
Sinopharm (02096) announced that on November 18, 2024, the company invested 1016.67 million...
SIMCERE PHARMA (02096) announced that on November 18, 2024, the company repurchased 1.49 million shares at a cost of 10.167 million Hong Kong dollars. The repurchase price was between 6.71 and 6.98 Hong Kong dollars per share.
Related Articles
YZYBIO-B (02496): Y225 (Emicizumab Injection) has obtained IND approval from the NMPA.
China Aluminum International Engineering Corporation (02068): The consortium signed the "Qingtongxia Aluminum Electrolytic Cell Large for Small Upgrading and Transformation Project EPC Engineering General Contract" with Qingtongxia Aluminum Company.
JINKE SERVICES (09666): The offeror has received acceptances for a total of 51.758 million shares.
YZYBIO-B (02496): Y225 (Emicizumab Injection) has obtained IND approval from the NMPA.
China Aluminum International Engineering Corporation (02068): The consortium signed the "Qingtongxia Aluminum Electrolytic Cell Large for Small Upgrading and Transformation Project EPC Engineering General Contract" with Qingtongxia Aluminum Company.
JINKE SERVICES (09666): The offeror has received acceptances for a total of 51.758 million shares.
RECOMMEND
